NovaBay Pharmaceuticals (NBY) 10-Q 10 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 09, 2016
Document Information [Line Items]
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Entity Central Index Key	1,389,545
Trading Symbol	nby
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		15,134,971
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 9,430	$ 2,385
Accounts receivable, net of allowance for doubtful accounts ($14 and $40 at September 30, 2016 and December 31, 2015, respectively)	2,079	536
Inventory, net of allowance for obsolete inventory and lower cost of market ($77 and $45 at September 30, 2016 and December 31, 2015, respectively)	1,084	1,345
Prepaid expenses and other current assets	1,827	261
Total current assets	14,420	4,527
Property and equipment, net	282	395
Other assets	439	155
TOTAL ASSETS	15,141	5,077
Current liabilities:
Accounts payable	387	2,483
Accrued liabilities	1,880	1,980
Deferred revenue	1,461	170
Total current liabilities	3,728	4,633
Deferred revenues - non-current	1,913	2,248
Deferred rent	248	189
Notes payable, related party		1,655
Warrant liability	2,336	1,450
Other liabilities	198
Total liabilities	8,423	10,175
Stockholders' equity (deficit):
Common stock, $0.01 par value; 240,000,000 shares authorized, 14,865,507 and 3,486,232 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	149	35
Additional paid-in capital	108,592	85,387
Accumulated deficit	(102,023)	(90,520)
Total stockholders' equity (deficit)	6,718	(5,098)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 15,141	$ 5,077

Consolidated Balance Sheets (C3

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accounts receivable, allowance for doubtful accounts	$ 14	$ 40
Inventory, allowance for obsolete inventory accounts and lower cost market	$ 77	$ 45
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	240,000,000	240,000,000
Common stock, shares issued (in shares)	14,865,507	3,486,232
Common stock, shares outstanding (in shares)	14,865,507	3,486,232

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Sales:
Product revenue	$ 3,262	$ 1,136	$ 7,571	$ 2,559
Other revenue	176	64	249	187
Total net sales	3,438	1,200	7,820	2,746
Product cost of goods sold	566	269	1,656	670
Gross profit	2,872	931	6,164	2,076
Research and development	4	1,563	1,215	4,503
Sales and marketing	2,663	3,035	8,660	7,260
General and administrative	2,218	1,681	5,131	5,181
Total operating expenses	4,885	6,279	15,006	16,944
Operating Loss	(2,013)	(5,348)	(8,842)	(14,868)
Non-cash (loss) gain on changes in fair value of warrant liability	(1,671)	139	(2,480)	173
Other expense, net	(52)	(31)	(179)	(64)
Loss before provision for income taxes	(3,736)	(5,240)	(11,501)	(14,759)
Provision for income tax		(2)	(2)	(10)
Net loss and comprehensive loss	$ (3,736)	$ (5,242)	$ (11,503)	$ (14,769)
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	$ (0.34)	$ (1.77)	$ (1.54)	$ (5.68)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (in shares)	10,912,616	2,957,477	7,480,985	2,598,052

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities:
Net loss	$ (11,503)	$ (14,769)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	98	123
Gain on disposal of property and equipment	(232)	(1)
Stock-based compensation expense for options and stock issued to employees and directors	889	869
Stock-based compensation expense for options and stock issued to consultants and advisory board members	185	140
Issuance of Restricted Stock Units (“RSUs") to employees	133
Issuance of RSUs to consultants and advisory board members	20
Warrant modification	270
Note receivable impairment	91
Leasehold improvements impairment	66
Non-cash loss (gain) on change in fair value of warrant liability	2,480	(173)
Changes in operating assets and liabilities:
Accounts receivable	(1,544)	(307)
Inventory	261	(1,001)
Prepaid expenses and other assets	(1,433)	1
Other long-term assets	(374)
Accounts payable and accrued liabilities	(2,061)	1,057
Deferred rent	59	15
Deferred revenue	956	(24)
Long-term obligations	198
Net cash used in operating activities	(11,441)	(14,070)
Investing activities:
Purchases of property and equipment	(78)	(46)
Proceeds from disposal of property and equipment		37
Net cash used in investing activities	(78)	(9)
Financing activities:
Proceeds from common stock issuances, net	13,648
Proceeds from exercise of warrants, net	6,571
Proceeds from borrowings	1,365
Repayment of borrowings	(3,020)
Proceeds from shelf offering, net		12,033
Net cash provided by financing activities	18,564	12,033
Net increase (decrease) in cash and cash equivalents	7,045	(2,046)
Cash and cash equivalents, beginning of period	2,385	5,429
Cash and cash equivalent, end of period	9,430	3,383
Supplemental disclosure of non-cash information
Stock issued to consultants for services, included in accounts payable and accrued liabilities	7
Fixed asset purchases, included in accounts payable and accrued liabilities	20
Exchange of equipment for services	279
Interest paid	$ 51

Note 1 - Organization

Note 1 - Organization	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. ORGANIZATION NovaBay Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company focused on commercializing prescription Avenova® daily lid and lash hygiene in the domestic eye care market. The Company was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc. It had no operations until July 1, 2002, on which date it acquired all of the operating assets of NovaCal Pharmaceuticals, LLC, a California limited liability company. In February 2007, it changed its name from NovaCal Pharmaceuticals, Inc. to NovaBay Pharmaceuticals, Inc. In August 2007, it formed two subsidiaries––NovaBay Pharmaceuticals Canada, Inc., a wholly-owned subsidiary incorporated under the laws of British Columbia (Canada), which was formed to conduct research and development in Canada and was dissolved in July 2012, and DermaBay, Inc., a wholly-owned U.S. subsidiary, which was formed to explore dermatological opportunities and was dissolved in April 2016. In June 2010, the Company changed the state in which it is incorporated (the “Reincorporation”), and is now incorporated under the laws of the State of Delaware. All references herein to “the Company” refer to the California corporation prior to the date of the Reincorporation, and to the Delaware corporation on and after the date of the Reincorporation . Effective December 18, 2015, the Company effected a 1-for-25 reverse split of its outstanding common stock (the “Reverse Stock Split”) (See Note 11). The accompanying financial statements and related notes give retroactive effect to the Reverse Stock Split. Need to Raise Additional Capital The Company has incurred significant losses from operations since inception and expects losses to continue until the Company reaches its goal of becoming cash flow breakeven from operations. The Company currently expects to reach positive cash flow from operations by the end of December 2016. As of September 30, 2016, the Company had cash and cash equivalents of $9.4 million. The Company’s operating plans call for cash expenditures to exceed $19.4 million over the next twelve months. Even if the Company becomes cash flow breakeven from operations, the Company may need to raise additional capital to fund its operations, including through the sale of equity securities, debt arrangements or partnership or licensing collaborations. Such funding may not be available or may not be on terms that are favorable to the Company. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and its ability to continue as a going concern. If the Company becomes unable to continue as a going concern, it may have to liquidate its assets and might realize significantly less value than the values at which such assets are carried on its financial statements, and stockholders may lose all or part of their investment in Company common stock. The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions for Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and notes required for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 4, 2016. The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries, as applicable. Reclassifications Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not change total assets, total liabilities, or total stockholders’ equity (deficit). Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, DermaBay, Inc., as applicable. DermaBay, Inc. was dissolved by the Company in April 2016. All inter-company accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates. Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. Cash, Cash Equivalents and Short-Term Investments The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of September 30, 2016, and December 31, 2015, the Company’s cash and cash equivalents were held in three highly-rated, major financial institutions in the United States. The Company classifies all highly-liquid investments with a stated maturity of greater than three months at the date of purchase as short-term investments. Short-term investments generally consist of municipal and corporate debt securities. The Company has classified its short-term investments as available-for-sale. The Company does not intend to hold securities with stated maturities greater than twelve months until maturity. These securities are carried at fair value, with the unrealized gains and losses reported as a component of other comprehensive (loss) until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value below cost of any available-for-sale security that is determined to be other-than-temporary results in a revaluation of its carrying amount to fair value and an impairment charge to earnings, resulting in a new cost basis for the security. No such impairment charges were recorded for the periods presented. The interest income and realized gains and losses are included in other expense, net, within the consolidated statements of operations and comprehensive loss. Interest income is recognized when earned. As of September 30, 2016 and December 31, 2015, the Company had no short-term investments. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with three highly-rated, major financial institutions in the United States. Deposits in these banks may exceed the amount of federal insurance provided on such deposits. The Company does not believe it is exposed to significant credit risk due to the financial position of the financial institutions in which these deposits are held. During the three months and nine months ended September 30, 2016, revenues were derived primarily from sales of Avenova directly to doctors through the Company’s webstore and to three major distribution partners. During the three months and nine months ended September 30, 2015, revenues were derived primarily from one collaboration partner, service revenues and sales of NeutroPhase. As of September 30, 2016, 36%, 25% and 17% of accounts receivable were from three major distribution partners. As of December 31, 2015, 41% and 18% of accounts receivable were from two major distribution partners. Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Our warrant liability is carried at fair value. The Company measures the fair value of financial assets and liabilities based on GAAP guidance, which defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. Under GAAP, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is also established, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities; Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identified amounts due that are in dispute and it believes are unlikely to be collected as of the end of September 30, 2016. As of September 30, 2016 and December 31, 2015, management had reserved $14 thousand and $40 thousand, respectively, primarily based on specific amounts that are in dispute and are over 120 days past due. Inventory Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes, and pumps; (2) goods in progress, which are normally unlabeled bottles; and (3) finished goods. Inventory is stated at the lower of cost or market value determined by the first-in, first-out method. The inventory allowance for lower cost or market, obsolete inventory, and excess inventory was $77 thousand and $45 thousand at September 30, 2016 and December 31, 2015, respectively. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five to seven years for office and laboratory equipment, three years for software and seven years for furniture and fixtures. Leasehold improvements are depreciated over the shorter of seven years or the lease term. The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred. In September 2016, the Company sub-leased its prior headquarters and determined that its leasehold improvements were impaired. This resulted in a $66 thousand impairment charge recorded to general and administrative expense for the third quarter of 2016, and is reflected in the results for the three and nine months ended September 30, 2016. Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with GAAP, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use are present. Management periodically evaluates the carrying value of long-lived assets. During the first quarter of fiscal year 2016, the Company impaired a note receivable which was deemed to no longer be collectable, as the originator of the loan is not in business and the collateral held against the loan did not possess value in an amount sufficient to satisfy the loan. As a result, a $91 thousand impairment charge was recorded to research and development expense for the first quarter of fiscal year 2016, and is reflected in the results of the nine months ended September 30, 2016. There were no impairments during the three and nine months ended September 30, 2015. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the statements of operations. Comprehensive Income (Loss) Accounting Standards Codification (“ASC”) 220, Comprehensive Income Revenue Recognition The Company sells products through a limited number of distributors and via its webstore. The Company generally records product sales upon shipment to the final customer for its webstore sales and upon shipment from its distributor to the final customers for its major distribution partners. The Company recognizes product revenue when: (i) persuasive evidence that a sale arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured. Revenue from sales transactions where the customer has the right to return the product is recognized at the time of sale only if: (i) the Company’s price to the customer is substantially fixed or determinable at the date of sale, (ii) the customer has paid the Company, or the customer is obligated to pay the Company and the obligation is not contingent on resale of the product, (iii) the customer's obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (iv) the customer acquiring the product for resale has economic substance apart from that provided by the Company, (v) the Company does not have significant obligations for future performance to directly bring about resale of the product by the customer, and (vi) the amount of future returns can be reasonably estimated. If these factors were to vary, the resulting change could have a material effect on our revenue recognition and on the Company’s results of operations. Product Revenue Allowances Product revenue is recognized, net of cash consideration paid to our customers and wholesalers, for services rendered by wholesalers in accordance with such wholesalers’ agreements and includes both a fixed rate per prescription shipped and monthly program management and data fees. These services are not deemed sufficiently separable from the customers' purchase of the product; therefore, they are recorded as a reduction of revenue at the time of revenue recognition. Other product revenue allowances include certain prompt pay discounts and allowances offered to our customers, program rebates and chargebacks. These product revenue allowances are recognized as a reduction of revenue or as a selling expense at the later of the date at which the related revenue is recognized or the date at which the allowance is offered. Other Revenue License and collaboration revenue is primarily generated through agreements with strategic partners for the development and commercialization of the Company’s product candidates. The terms of the agreements typically include non-refundable upfront fees, funding of research and development activities, and payments based upon achievement of certain milestones and royalties on net product sales. In accordance with authoritative guidance, the Company analyzes its multiple element arrangements to determine whether the elements can be separated. The Company performs its analysis at the inception of the arrangement and as each product or service is delivered. If a product or service is not separable, the combined deliverables are accounted for as a single unit of accounting, and revenue is recognized over the performance obligation period. The Company recognizes other revenue when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and risk of loss has passed; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured. If these factors were to vary, the resulting change could have a material effect on the Company’s revenue recognition and results of operations. Cost of Goods Sold Cost of goods sold includes third party manufacturing costs, shipping costs, and other cost of goods sold. Cost of goods sold also includes any necessary allowances for excess inventory that may expire and become unsalable. The amount charged for lower cost or market, obsolete inventory, and excess inventory expensed was $47 thousand and $84 thousand for the three and nine month periods ended September 30, 2016, respectively. The amount charged for lower cost or market, obsolete inventory, and excess inventory expensed was zero for the three and nine month periods ended September 30, 2015. Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may vary depending on the type of item or service incurred, location of performance or production, level of availability of the item or service, and specificity required in production for certain compounds. The Company uses external service providers to conduct clinical trials, to manufacture supplies of product candidates and to provide various other research and development-related products and services. The Company’s research, clinical and development activities are often performed under agreements it enters into with external service providers. The Company estimates and accrues the costs incurred under these agreements based on factors such as milestones achieved, patient enrollment, estimates of work performed, and historical data for similar arrangements. As actual costs are incurred, the Company adjusts its accruals. Historically, the Company’s accruals have been consistent with management’s estimates, and no material adjustments to research and development expenses have been recognized. Subsequent changes in estimates may result in a material change in the Company’s expenses, which could also materially affect its results of operations. Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Updates (“ASU”) No. 2014-12, Compensation-Stock Compensation (Topic 718) Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized. Common Stock Warrant Liability For warrants that are issued or modified and there is a deemed possibility that the Company may have to settle the warrants in cash, or for warrants the Company issues or modifies that contain an exercise price adjustment feature that reduces the exercise price of the Company’s common stock eligible for purchase thereunder in the event that the Company subsequently issues equity instruments at a price lower than the exercise price of the warrants, the Company records the fair value of the issued or modified warrants as a liability at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss on the consolidated statements of operations and comprehensive loss. The fair values of these warrants have been determined using the Binomial Lattice (“Lattice”) valuation model, which provides for assumptions regarding volatility, call and put features and risk-free interest rates within the total period to maturity. These values are subject to a significant degree of the Company’s judgment. Net (Loss) per Share The Company computes net (loss) per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods since their effect would be anti-dilutive. During the three months ended September 30, 2016 and 2015, and the nine months ended September 30, 2016 and 2015, there was no difference between basic and diluted EPS due to the Company’s net losses. The following table sets forth the calculation of basic EPS and diluted EPS: Three Months Ended Nine Months Ended September 30, September 30, (in thousands, except per share data) 2016 2015 2016 2015 Net loss $ (3,736 ) $ (5,242 ) $ (11,503 ) $ (14,769 ) Basic Shares 10,912,616 2,957,477 7,480,985 2,598,052 Add: shares issued upon assumed exercise of stock options and warrants — — — — Diluted shares 10,912,616 2,957,477 7,480,985 2,598,052 Basic and diluted net loss per share $ (0.34 ) $ (1.77 ) $ (1.54 ) $ (5.68 ) The following outstanding stock options and stock warrants were excluded from the diluted net loss per share computation, as their effect would have been anti-dilutive: Nine Months Ended September 30, (in thousands) 2016 2015 Period end stock options to purchase common stock 1,502 344 Period end common stock warrants 929 1,015 2,431 1,359 Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) In March, April and May 2016, the FASB issued additional amendments to the new revenue guidance relating to reporting revenue on a gross versus net basis, identifying performance obligations, licensing arrangements, collectability, noncash consideration, presentation of sales tax, and transition. This new standard will replace all current GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition update guidance provides a unified model to determine how revenue is recognized. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The FASB has issued several updates to the standard which i) clarify the application of the principal versus agent guidance (ASU 2016-08); ii) clarify the guidance on inconsequential and perfunctory promises and licensing (ASU 2016-10) and iii) narrow-scope improvements and practical expedients (ASU 2016-12). On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. The Company is currently assessing the potential impact of this new standard on its consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory In August 2014, FASB issued ASU 2014-15, Presentation of Financial Statements Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Leases (Topic 840) In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230), effects of the adoption of ASU 2016-15 to its consolidated financial statements.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. FAIR VALUE MEASUREMENTS The Company measures the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three levels for measuring fair value, and requires disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s warrant liability is classified within Level 3 of the fair value hierarchy because the value is calculated using significant judgment based on the Company’s own assumptions in the valuation of this liability. The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016: Fair Value Measurements Using (in thousands) Balance at September 30, 2016 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 100 $ 100 $ — $ — Total assets $ 100 $ 100 $ — $ — Liabilities Warrant liability $ 2,336 $ — $ — $ 2,336 Total liabilities $ 2,336 $ — $ — $ 2,336 For the three and nine month periods ended September 30, 2016, as a result of the fair value adjustment of the warrant liability, the Company recorded a non-cash expense on an increase in the fair value of the warrants of $1,671 thousand and $2,480 thousand, respectively, in its consolidated statement of operations and comprehensive loss. See Note 10 for further discussion of the calculation of the fair value of the warrant liability. (in thousands) Warrant liability Fair value of warrant liability at December 31, 2015 $ 1,450 Increase in fair value at March 31, 2016 385 Fair value of warrant liability at March 31, 2016 1,835 Increase in fair value at June 30, 2016 424 Fair value of warrant liability at June 30, 2016 2,259 Increase in fair value on exercise date and at September 30, 2016 1,671 Fair market value of warrants transferred to equity upon exercise (1,594 ) Fair value of warrant liability at September 30, 2016 $ 2,336

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. PREPAID EXPENSES AND OTHER ASSETS Prepaid expenses and other current assets consisted of the following: (in thousands) September 30, 2016 December 31, 2015 Prepaid outsourced sales team $ 646 $ — Prepaid sales rebate 530 — Prepaid rent 196 — Prepaid research and development services 140 — Inventory deposit 29 84 Other 286 177 Total prepaid expenses and other current assets $ 1,827 $ 261

Note 5 - Inventory

Note 5 - Inventory	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5. INVENTORY Inventory consisted of the following: (in thousands) September 30, 2016 December 31, 2015 Raw materials and supplies $ 769 $ 660 Goods in process — 248 Finished goods 392 482 Less allowance for obsolete inventory and lower cost of market (77 ) (45 ) Total inventory $ 1,084 $ 1,345

Note 6 - Property and Equipment

Note 6 - Property and Equipment	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. PROPERTY AND EQUIPMENT Property and equipment consisted of the following: (in thousands) September 30, 2016 December 31, 2015 Office and laboratory equipment $ 214 $ 1,633 Furniture and fixtures 183 254 Software 100 37 Leasehold improvements 181 173 Total property and equipment, at cost 678 2,097 Less: accumulated depreciation (396 ) (1,702 ) Net property and equipment $ 282 $ 395 In September 2016, the Company sub-leased its prior headquarters and determined that its leasehold improvements were impaired. This resulted in a $66 thousand impairment charge recorded to general and administrative expense for the third quarter of 2016, and is reflected in the results for the three and nine months ended September 30, 2016. In September 2016, the Company transferred title to a significant portion of its lab equipment in exchange for research and development services. As a result, the Company recognized a $232 thousand gain on the sales of these assets, which was recorded to research and development expense for the third quarter of fiscal year 2016, and is reflected in the results for the three and nine months ended September 30, 2016. Depreciation and amortization expense was $31 thousand and $41 thousand for the three months ended September 30, 2016 and 2015, respectively, and $98 thousand and $123 thousand for the nine months ended September 30, 2016 and 2015, respectively.

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 7. ACCRUED LIABILITIES Accrued liabilities consisted of the following: (in thousands) September 30, 2016 December 31, 2015 Research and development $ 12 $ 394 Employee payroll and benefits 449 614 Severance pay 512 590 Inventory 130 12 Sales rebate 149 150 Outsourced sales team 299 - Other 329 220 Total accrued liabilities $ 1,880 $ 1,980

Note 8 - Related Party Notes Pa

Note 8 - Related Party Notes Payable	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Related Party Notes Payable [Text Block]	NOTE 8. RELATED PARTY NOTES PAYABLE Beginning on December 30, 2015, the Company entered into a series of agreements pursuant to a loan (the “Loan”) facilitated by China Kington Asset Management Co. Ltd. (“China Kington”). In connection with the Loan, the Company issued five (5) promissory notes (the “Notes”) payable to Mr. Mark Sieczkarek, the Gail J. Maderis Revocable Trust, Dr. T. Alex McPherson, Mr. Jian Ping Fu, and Pioneer Pharma (Singapore) Pte. Ltd. (“Pioneer Singapore”) The proceeds from the Notes were used for general corporate purposes. Minimum In connection with the Notes, China Kington agreed to act as collateral agent for the benefit of the Lenders, in accordance with the terms of a collateral agency and intercreditor agreement (the “Collateral Agency Agreement”), which was entered into on December 30, 2015 between China Kington and the Lenders. To secure the Notes, China Kington perfected a security interest in all tangible and intangible assets of the Company, pursuant to a security agreement (the “Security Agreement” ) As consideration to China Kington for facilitating the Loan, the Company agreed to the following: (1) the grant of a first right of refusal for China Kington (or its designee that shall be acceptable to the Company in its reasonable discretion) to lead financings for the Company for a period that is the shorter of two (2) years or the day that the Company’s cash flow has been equal to or greater than $0 in each month for three (3) consecutive months, subject to certain limitations; (2) the participation of Mr. Sieczkarek as a Lender in the financing; (3) the participation of the Company’s Board of Directors, management and investors that the Board of Directors and management provide, to contribute an aggregate nine percent (9%) of funds in the Company’s next financing; (4) the appointment of two new members to the Company’s Board by China Kington; and (5) the Company’s agreement to reasonably cooperate with reasonable requests made by an auditor engaged, and paid for, by China Kington, subject to certain limitations. Upon the recommendation of China Kington, and after reviewing their relevant experiences and background and discussing the same, on January 26, 2016 the Board of Directors unanimously appointed Mr. Mijia “Bob” Wu and Mr. Xiaoyan “Henry” Liu to serve as Class I and Class III members of the Company’s Board, respectively. Upon closing the first tranche of an $11.8 million private placement on May 6, 2016 and by agreement with the Lenders, the Company used $2.5 million of the proceeds from the private placement to repay principal on the Notes issued to the Lenders. Upon closing the second tranche of such $11.8 million private placement on August 1, 2016, the Company repaid the remaining principal on the Notes in the amount of $520 thousand.

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 9. COMMITMENTS AND CONTINGENCIES Operating Leases On August 24, 2016, the Company entered into an Office Lease (the “Lease”), pursuant to which the Company leased approximately 7,799 rentable square feet of real property located on the eleventh floor (Suite 1150) at 2000 Powell Street, Emeryville, California 94608 (the “Premises”) from KBSIII Towers at Emeryville, LLC (the “Landlord”), for the Company’s new principal executive offices. The expiration date of the Lease is February 28, 2022, which is the last day of the month sixty-three (63) months following the month in which the commencement date occurs (the “Lease Term”), unless earlier terminated pursuant to any provision of the Lease. Under the Lease, the Company has the option to occupy temporary space in the same building at 2000 Powell Street until the leased Premises are completed. The Company is currently utilizing the option to occupy the temporary space, but expects to occupy Suite 1150 as of December 1, 2016. The Company also has the option to extend the term of the Lease for one five (5)-year period upon written notice to the Landlord which is no earlier than twelve (12) months and no later than nine (9) months prior to the expiration of the then current term. The effective monthly base rental rate for the first twelve (12) months of the Lease is $4.15 per square foot ($338,390 annually), and increases approximately three percent (3%) every eleven (11) months thereafter beginning with the thirteenth (13 th th The Company leases laboratory facilities and office space at Suite 550, EmeryStation North Building, 5980 Horton Street, Emeryville, California (“EmeryStation”) under an operating lease which will expire on October 21, 2020. On July 11, 2016, the Company entered into a Sublease Agreement to sublease 16,465 rentable square feet of real property at EmeryStation (the “Sublease Agreement”). The commencement date under the Sublease Agreement was September 8, 2016. The expiration date of the Sublease Agreement is October 21, 2020, the expiration date of the Company’s lease for the Premises, as amended, unless earlier terminated pursuant to any provision of the Company’s lease for EmeryStation, as amended, or the Sublease Agreement. As a result of the sublease, the Company recorded a non-cash loss of $26 thousand, and an impairment to leasehold improvements of $66 thousand, which were recorded to general and administrative expense. Rent expense was approximately $360 thousand and $257 thousand for the three months ended September 30, 2016 and 2015, respectively. Rent expense was approximately $873 thousand and $758 thousand for the nine months ended September 30, 2016 and 2015, respectively. The Company’s monthly rent payments fluctuate under the various lease and sublease agreements. In accordance with GAAP, the Company recognizes rent expense on a straight-line basis. The Company records deferred rent and sublease future minimum payments receivable for the difference between the amounts paid and recorded as expense. Directors and Officers Indemnity As permitted under Delaware law and in accordance with its bylaws, the Company shall indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving at its request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable the Company to recover a portion of any future payments. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, no liability has been recorded for these agreements as of September 30, 2016. In the normal course of business, the Company provides indemnification of varying scope under agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, the Company generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third party with respect to their products. The term of these indemnification agreements is generally perpetual. The potential future payments the Company could be required to make under these indemnification agreements is unlimited. Historically, costs related to these indemnification provisions have been immaterial. The Company also maintains various liability insurance policies that limit its exposure. As a result, the Company believes the fair value of these indemnification agreements is minimal. Accordingly, no liabilities have been recorded for these agreements as of September 30, 2016. Legal Matters From time to time, the Company may be involved in various legal proceedings arising in the ordinary course of business. There are no matters as of September 30, 2016, that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Company’s financial position, results of operations or cash flows.

Note 10 - Warrant Liability

Note 10 - Warrant Liability	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 10. WARRANT LIABILITY In July 2011, the Company sold common stock and warrants in a registered direct financing. As part of this transaction, 139,520 warrants were issued with an exercise price of $33.25 and were exercisable from January 1, 2012 to July 5, 2016. The terms of the warrants require registered shares to be delivered upon each warrant’s exercise and also require possible cash payments to the warrant holders (in lieu of the warrant’s exercise) upon specified fundamental transactions involving the Company’s common stock, such as an acquisition of the Company. Under ASC 480, Distinguishing Liabilities from Equity In October 2015, the holders of all warrants issued pursuant to the Company’s securities purchase agreement dated March 3, 2015 (the “March SPA”) agreed to reduce the length of notice required to such investors prior to the Company’s issuance of new securities from twenty business days to two business days, for the remainder of such investors’ pre-emptive right period (which expired March 3, 2016). The Company entered into these agreements to enable it to expeditiously raise capital in its October 2015 offering (as described below) and future offerings. As consideration for these agreements, the Company amended certain provisions of both warrants issued with a 15-month term (the “Short-Term Warrants”) and warrants issued with a 60-month term (the “Long-Term Warrants”) pursuant to the March SPA (together, the “March 2015 Warrants”) and the warrants issued pursuant to the placement agent agreement dated June 29, 2011 (the “July 2011 Warrants”). Specifically, the amendments decreased the exercise price for both the March 2015 Warrants and the July 2011 Warrants to $5.00 per share. In addition, the amendments extended the exercise expiration date for the Short-Term Warrants and the July 2011 Warrants to March 6, 2020. A price protection provision also was added to both the July 2011 Warrants and the March 2015 Warrants, such that if the Company subsequently sells or otherwise disposes of Company common stock at a lower price per share than $5.00 or any securities exchangeable for common stock with a lower exercise price per share than $5.00, the exercise price of such warrants will be reduced to that lower price. In October 2015, the Company also entered into an underwriting agreement with Roth Capital Partners, LLC, relating to the public offering and sale of up to (i) 492,000 shares of the Company’s common stock; and (ii) warrants to purchase up to 442,802 shares of the Company’s common stock with an exercise price of $5.00 per share. The shares of common stock and warrants were issued separately. Each warrant was exercisable immediately upon issuance and will expire 60 months from the date of issuance. The price to the public in this offering was $5.00 per share of common stock and related warrant. The net proceeds to the Company were approximately $2.1 million after deducting underwriting discounts and commissions and offering expenses. In February 2016, the strike price of the July 2011, March 2015 and October 2015 warrants was reduced to $1.81 per share, pursuant to the price protection provisions in such warrants, because the Company sold common stock to Mr. Jian Ping Fu at that price. The Company evaluated the change in terms of the July 2011 warrants and noted that the change in terms resulted in a revaluation at the time of the change. The warrants were re-issued and valued as of October 27, 2015 at $361 thousand with the new terms, and a modification expense was recorded for the difference between the fair value of the warrants at their new terms after modification on October 27, 2015 and the fair value of the warrants at their original terms prior to modification as of October 27, 2015. The fair values of these warrants have been determined using the Lattice valuation model, and the changes in the fair value are recorded in the consolidated statement of operations. The key assumptions used to value the warrants after modification at October 27, 2015 were as follows: Assumption Expected price volatility 80.00 % Expected term (in years) 4.36 Risk-free interest rate 1.23 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.60 The key assumptions used to value the July 2011 Warrants after modification as of September 30, 2016, and December 31, 2015 were as follows: Period Ended Assumption September 30, 2016 December 31, 2015 Expected price volatility 100.00 % 80.00 % Expected term (in years) 3.43 4.18 Risk-free interest rate 0.94 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.14 $ 1.10 In March 2015, the Company issued both the Short-Term Warrants ($15.00 per share exercise price) and the Long-Term Warrants ($16.25 per share exercise price). At that time, the Company determined that these warrants qualified for equity accounting and did not contain embedded derivatives that required bifurcation. After the Company’s agreement to modify the terms of the March 2015 Warrants and July 2011 Warrants in October 2015, the Company evaluated the change in terms of the March 2015 Warrants and noted that the change in terms resulted in liability classification of both the Short-Term and Long-Term Warrants. The March 2015 Warrants were re-issued and valued as of October 27, 2015 at a total of $1.8 million with the new terms, and a modification expense was recorded at the difference between the fair value of the warrants on their new terms after modification as of October 27, 2015 and the fair value of the warrants on their original terms prior to modification as of October 27, 2015. The fair values of these warrants have been determined using the Lattice valuation model, and the changes in the fair value are recorded in the consolidated statement of operations. The key assumptions used to value the Short-Term and Long-Term Warrants after modification at October 27, 2015 were as follows: Assumption Expected price volatility 80.00 % Expected term (in years) 4.36 Risk-free interest rate 1.23 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.78 The key assumptions used to value the Short-Term Warrants after modification as of September 30, 2016, and December 31, 2015 were as follows: Period Ended Assumption September 30, 2016 December 31, 2015 Expected price volatility 100.00 % 80.00 % Expected term (in years) 3.43 4.18 Risk-free interest rate 0.94 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.23 $ 1.16 The key assumptions used to value the Long-Term Warrants after modification as of September 30, 2016, and December 31, 2015 were as follows: Period Ended Assumption September 30, 2016 December 31 , 2015 Expected price volatility 100.00 % 80.00 % Expected term (in years) 3.43 4.18 Risk-free interest rate 0.94 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.22 $ 1.16 As noted above, in October 2015, the Company issued warrants in connection with an underwriting agreement. The Company evaluated the terms of the warrants and noted that under ASC 480, the Company’s potential obligation to cash-settle the warrants if specified fundamental transactions occur are deemed to be beyond the Company’s control. Due to this provision, ASC 480 requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Lattice valuation model, and the changes in the fair value are recorded in the consolidated statement of operations. The fair value of the warrants at issuance on October 27, 2015 was $1.3 million. The key assumptions used to initially value the October 2015 warrants at October 27, 2015 were as follows: Assumption Expected price volatility 75.50 % Expected term (in years) 5.00 Risk-free interest rate 1.38 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.82 The key assumptions used to value the warrants after modification as of September 30, 2016, and December 31, 2015 were as follows: Period Ended Assumption September 30, 2016 December 31, 2015 Expected price volatility 95.00 % 77.50 % Expected term (in years) 4.08 4.83 Risk-free interest rate 1.02 % 1.72 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.30 $ 1.21 During the third quarter of 2016, a total of 518,281 warrants to purchase 518,281 shares of common stock were exercised related to the July 2011, March 2015 and October 2015 warrants resulting in gross proceeds of $938 thousand. Upon exercise, the warrant liability associated with these warrants was adjusted to its fair value as of the date of exercise, with any change in fair value recorded in the consolidated income statement and comprehensive loss. The non-cash loss of $1.6 million was recorded as a result of these warrant liability revaluations, which was subsequently transferred to equity as of the date of their exercise. The details of all outstanding warrant liability as of September 30, 2016, were as follows: Dollars in thousands Shares Warrant Liability July 2011 Warrants 100,507 $ 316 Long-Term Warrants 127,919 413 Short-Term Warrants 172,667 556 October 2015 Warrants 318,602 1,051 719,695 $ 2,336

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Deficit)	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 11. STOCKHOLDERS’ EQUITY (DEFICIT) Amendments to Articles of Incorporation – Reverse Stock Split Effective December 18, 2015, the Company amended its Certificate of Incorporation to affect a 1-for-25 reverse split of its outstanding common stock (the “Reverse Stock Split”). The Reverse Stock Split was approved by the Company’s stockholders on December 11, 2015. The accompanying financial statements and related notes give retroactive effect to this Reverse Stock Split. Preferred Stock Under the Company’s amended articles of incorporation, the Company is authorized to issue up to 5,000,000 shares of preferred stock in such series and with such rights and preferences as may be approved by the Board of Directors. As of September 30, 2016, and December 31, 2015, there were no shares of Company preferred stock outstanding. Common Stock In February 2016, the Company entered into three securities purchase agreements (the “Purchase Agreements”) for the sale of an aggregate of 1,518,567 shares of the Company’s common stock (the “Common Stock”) to accredited investors for a total of $2.8 million. The Company entered into the first purchase agreement with Mr. Jian Ping Fu (the “Fu Agreement”), pursuant to which the Company agreed to issue and sell to Mr. Fu 696,590 shares of Common Stock, at a per share price of $1.81, which was a five percent (5%) discount to the closing price of the Common Stock on February 16, 2016, the date of the Fu Agreement. The Company entered into the second purchase agreement with Pioneer Singapore (the “Pioneer Agreement”), pursuant to which the Company agreed to issue and sell to Pioneer Singapore 696,590 shares of Common Stock, at a per share price of $1.91, which was the closing price of the Common Stock on February 16, 2016 with no discount. The Company entered into a third purchase agreement with Mark M. Sieczkarek (the “Sieczkarek Agreement”), pursuant to which the Company agreed to issue and sell to Mr. Sieczkarek 125,387 shares of Common Stock, at a per share price of $1.91, which was the closing price of the Common Stock on February 16, 2016 with no discount. The Common Stock issued by the Company pursuant to the Purchase Agreements has not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. On April 4, 2016, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) for the sale of an aggregate 6,173,299 shares of Common Stock, par value $0.01 per share (the “Shares”) and warrants (the “Warrants”) exercisable for 3,086,651 Shares (the “Warrant Shares”) to accredited investors for an aggregate purchase price of $11.8 million (the “Private Placement”). The warrants have a 4-year term and an exercise price of $1.91, callable by the Company if the closing price of the Common Stock, as reported on the NYSE MKT, is $4.00 or greater for five sequential trading days. The Private Placement closed in two tranches, the first of which closed on May 5, 2016, resulting in proceeds to the Company of $7.8 million (the “Primary Closing”), and the second of which closed on August 1, 2016, resulting in proceeds of $4.0 million to the Company (the “Secondary Closing”). In the Primary Closing, the Company issued 4,079,058 shares of Common Stock and Warrants exercisable for 2,039,530 shares of Common Stock. In the Secondary Closing, the Company issued 2,094,241 shares of Common Stock and Warrants exercisable for 1,047,121 shares of Common Stock. Both the Primary Closing and the Secondary Closing were subject to the same terms, containing customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Purchasers (as defined below) and other obligations of the parties and termination provisions. The purchasers include Pioneer Singapore, which purchased 2,617,802 Shares and 1,308,902 Warrants, Mr. Jian Ping Fu, who purchased 1,937,173 Shares and 968,587 Warrants, the Company’s Chairman, President and CEO Mr. Mark M. Sieczkarek, who purchased 523,560 Shares and 261,780 Warrants, Mrs. Ping Huang, who purchased 523,560 Shares and 261,780 Warrants, Mr. Hai Dong Pang, who purchased 209,424 Shares and 104,712 Warrants, Mr. Yin Ping Wang, who purchased 104,712 Shares and 52,356 Warrants, Mr. Blake F. Andros, who purchased 100,000 Shares and 50,000 Warrants, and the Children’s Brain Disease Foundation, Dr. Dean Rider and Mr. Andy R. Geckler, each of whom purchased 52,356 Shares and 26,178 Warrants (collectively, the “Purchasers”). Messrs. Fu, Pang, Wang, Andros and Geckler, Dr. Dean Rider and the Children’s Brain Disease Foundation participated only in the Primary Closing, Mrs. Huang participated only in the Secondary Closing, and Pioneer Singapore and Mr. Sieczkarek participated in both the Primary Closing and the Secondary Closing. Pioneer Singapore and Messrs. Fu and Sieczkarek also participated in the Company’s previous private placement that closed on February 24, 2016. China Kington Asset Management Co. Ltd. served as placement agent in exchange for a commission equal to six percent (6%) of the gross proceeds received by the Company upon closing pursuant to the purchases by Pioneer, Mrs. Huang, and Messrs. Fu, Pang and Wang. Also on April 4, 2016, the Company entered into a separate registration rights agreement (the “Registration Rights Agreement”) with Messrs. Andros and Geckler, Dr. Rider, and the Children’s Brain Disease Foundation (the “Participating Purchasers”), pursuant to which the Company agreed to file as many registration statements with the SEC as may be necessary to cover the resale of the Shares and the Warrant Shares held by the Participating Purchasers, to use its commercially reasonable efforts to have all such registration statements declared effective within the time frames set forth in the Securities Purchase Agreement and the Registration Rights Agreement, and to keep such registration statements effective for the terms defined therein. The Company filed such Registration Statement to cover the resale of the Shares and Warrant Shares held by the Participating Purchasers with the SEC on June 9, 2016 and received effectiveness of such Registration Statement on June 20, 2016 (Registration Number 333-211943). During the third quarter of 2016, the Company recorded $6.6 million in net proceeds upon the exercise of 3,613,261 of the Company’s warrants for 3,613,261 shares of the Company’s Common Stock. As consideration for the facilitation of the exercise of certain of these warrants held by non-U.S. citizens domiciled outside of the United States, China Kington received a six percent (6%) commission on the aggregate proceeds to the Company pursuant to such exercises. The amount of such commission was approximately $338 thousand. Stock Warrants In February 2016, the strike prices of the July 2011, March 2015 Short-Term and Long-Term, and October 2015 warrants were reduced to $1.81 per share, pursuant to the price protection provisions in such warrants, because the Company sold common stock to Mr. Jian Ping Fu at that price. In May 2016, the Company issued 2,039,530 warrants at the Primary Closing pursuant to the Securities Purchase Agreement. Please see the preceding subsection, “Common Stock,” for further details. In August 2016, the Company issued 1,047,121 warrants at the Secondary Closing pursuant to the Securities Purchase Agreement. Please see the preceding subsection, “Common Stock,” for further details. Effective September 29, 2016, the Company modified the exercise price of all warrants issued pursuant to the securities purchase agreement, dated May 18, 2015, from $19.50 to $3.15 per share, which reflected a discount of approximately sixteen percent (16%) to the closing price of the Company’s Common Stock on September 27, 2016. The Company has estimated the value of warrant modification as of the date of the modification by applying the Black-Scholes-Merton option pricing model using the single-option valuation approach. As a result of this modification, the Company recorded a non-cash loss of $270 thousand in general and administrative expense. The details of all outstanding warrants as of September 30, 2016, are as follows: (in thousands, except for exercise price) Warrants Weighted- Average Exercise Price Warrants outstanding December 31, 2015 1,458 $ 5.19 Warrants granted 3,087 1.91 Warrants exercised (3,613 ) 1.91 Warrants expired (3 ) 78.13 Warrants outstanding September 30, 2016 929 $ 2.12

Note 12 - Equity-based Compensa

Note 12 - Equity-based Compensation	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 12. EQUITY-BASED COMPENSATION Equity Compensation Plans Prior to its Initial Public Offering (the “IPO”), the Company had two equity plans in place: the 2002 Stock Option Plan and the 2005 Stock Option Plan. Upon the closing of the IPO in October 2007, the Company adopted the 2007 Omnibus Incentive Plan (the “2007 Plan”) to provide for the granting of equity awards, such as stock options, unrestricted and restricted common stock, stock units, dividend equivalent rights, and stock appreciation rights to employees, directors and outside consultants, as determined by the Board. In conjunction with the adoption of the 2007 Plan, no further option awards may be granted under the 2002 or 2005 Stock Option Plans, and any option cancellations or expirations from the 2002 or 2005 Stock Option Plans may not be reissued. On May 26, 2016, the stockholders of the Company approved an amendment to the 2007 Plan to increase the number of shares of Company common stock reserved for issuance thereunder by 1,124,826 shares, for an aggregate 3,124,836 shares available under the 2007 Plan. As of September 30, 2016, there were 97,200 shares available for future grant under the 2007 Plan. Under the terms of the 2007 Plan, the exercise price of incentive stock options may not be less than 100% of the fair market value of the common stock on the date of grant and, if granted to an owner of more than 10% of the Company’s stock, then not less than 110% of the fair market value of the common stock on the date of grant. Stock options granted under the 2007 Plan expire no later than ten years from the date of grant. Stock options granted to employees generally vest over four years, while options granted to directors and consultants typically vest over a shorter period, subject to continued service. All of the options granted prior to October 2007 include early exercise provisions that allow for full exercise of the option prior to the option vesting, subject to certain repurchase provisions. The Company issues new shares to satisfy option exercises under the plans. Stock Option Summary The following table summarizes information about the Company’s stock options outstanding as of September 30, 2016, and activity during the nine-month period then ended: (in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2015 388 $ 32.03 6.2 19 Options granted 1,199 $ 2.71 Restricted stock units granted 74 $ — Options exercised - $ — Restricted stock units vested (74 ) $ — Options forfeited/cancelled/expired (85 ) $ 36.87 Outstanding at September 30, 2016 1,502 $ 8.64 8.9 $ 1,718 Vested and expected to vest at September 30, 2016 1,478 $ 8.40 8.9 $ 1,691 Vested at September 30, 2016 325 $ 27.04 6.2 $ — Exercisable at September 30, 2016 325 $ 27.04 6.2 $ — The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE MKT as of September 30, 2016 for options that have a quoted market price in excess of the exercise price. There were no stock option awards exercised for the three and nine months ended September 30, 2016. Accordingly, the Company received no cash payments for the exercise of stock options during the three and nine months ended September 30, 2016. There were no stock option awards exercised for the three months ended September 30, 2015. The aggregate intrinsic value of stock option awards exercised was $4 thousand for the nine months ended September 30, 2015. As of September 30, 2016, total unrecognized compensation cost related to unvested stock options and restricted stock was $1.9 million. This amount is expected to be recognized as stock-based compensation expense in the Company’s consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of 1.84 years. Stock Options and Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes-Merton option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2 for a description of the accounting policies that the Company applied to value its stock-based awards. During the nine months ended September 30, 2016 and 2015, the Company granted options to purchase an aggregate of 1,110,000 and 26,000 shares of common stock, respectively, to employees and directors. The weighted-average assumptions used in determining the value of options are as follows: Nine months ended September 30, Assumption 2016 2015 Expected price volatility 84 % 74 % Expected term (in years) 7.03 5.35 Risk-free interest rate 1.56 % 1.65 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.03 $ 10.00 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. Additionally, during the nine months ended September 30, 2016 and 2015, the Company issued 64,000 and 6,000 shares of common stock, respectively, to employees. For the three months ended September 30, 2016 and 2015, the Company recognized stock-based compensation expense of $610 thousand and $192 thousand, respectively, for stock-based awards to employees and directors. For the nine months ended September 30, 2016 and 2015, the Company recognized stock-based compensation expense of $1,022 thousand and $869 thousand, respectively, for stock based awards to employees and directors. In the second quarter of 2015, the Company modified stock options owned by two of its directors, Mr. Cashion and Mr. Wicks, each of whom retired at the Company’s 2015 annual meeting of stockholders in June 2015. All outstanding stock options held by Mr. Cashion and Mr. Wicks became fully vested upon retirement, and the option exercise period for Mr. Cashion and Mr. Wicks was extended from three months to four years, calculated from the date of retirement. Options with an expiration date prior to the end of the exercise period maintained the same expiration date. In connection with the stock option modification, the Company recognized stock-based compensation expense of $185 thousand. During the second and third quarters of 2016, the Company modified stock options held by two of its directors, Mr. Radaelli and Mr. McPherson, each of whom resigned as directors of the Company, effective May 6, 2016 and August 24, 2016, respectively. All outstanding stock options held by Mr. Radaelli and Mr. McPherson became fully vested upon retirement, and the option exercise period for Mr. Radaelli and Mr. McPherson was extended from three months to four years, calculated from each former director’s respective date of resignation. Options with an expiration date prior to the end of the exercise period maintained the same expiration date. In connection with the stock option modification, the Company recognized stock-based compensation expense of $58 thousand. Stock-Based Awards to Non-Employee Consultants During the nine months ended September 30, 2016 and 2015, the Company granted options to purchase an aggregate of 89,000 and 12,000 shares of common stock, respectively, to non-employee consultants in exchange for advisory and consulting services. The stock options are recorded at their fair value on the measurement date and recognized over the respective service or vesting period. The fair value of the stock options granted was calculated using the Black-Scholes-Merton option pricing model based upon the following assumptions: Nine Months Ended September 30, Assumption 2016 2015 Expected price volatility 88 % 79 % Expected term (in years) 9.99 9.38 Risk-free interest rate 1.61 % 2.07 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.29 $ 13.50 The Company granted restricted stock to non-employee consultants totaling 10,000 and 1,000 shares of common stock in the nine months ended September 30, 2016 and 2015, respectively, in exchange for advisory and consulting services. For the three months ended September 30, 2016 and 2015, the Company recognized stock-based compensation expense of $100 thousand and $29 thousand, respectively, related to non-employee consultant stock and option grants. For the nine months ended September 30, 2016 and 2015, the Company recognized stock-based compensation expense of $205 thousand and $140 thousand, respectively, related to non-employee consultant stock and option grants. Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in the consolidated statement of operations and comprehensive loss for the options and common stock discussed above is as follows. The amounts that would have been charged to cost of goods sold are not material and have been included in general and administrative expense below. Three Months Ended Nine Months Ended September 30, September 30, (in thousands) 2016 2015 2016 2015 Research and development $ 63 $ 86 $ 142 $ 266 Sales and marketing 62 - 113 - General and administrative 585 135 972 743 Total stock-based compensation expense $ 710 $ 221 $ 1,227 $ 1,009 Since the Company continues to operate at a net loss, it does not expect to realize any current tax benefits related to stock options.

Note 13 - License, Collaboratio

Note 13 - License, Collaboration and Distribution Agreements	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	NOTE 13. LICENSE, COLLABORATION AND DISTRIBUTION AGREEMENTS Virbac Agreement In April 2012, the Company entered into a feasibility and option agreement with Virbac, a global animal health company, for the development and potential commercialization of Aganocides for a number of veterinary uses for companion animals. Under the terms of the agreement, the Company received an upfront payment and is entitled to additional support for research and development. Virbac conducted veterinary studies using the Company’s Aganocide compounds to assess feasibility for treating several veterinary indications. In April 2013, the option was exercised, and the Company entered into a collaboration and license agreement with Virbac. Under this agreement, Virbac acquired exclusive worldwide rights to develop the Company’s proprietary Aganocide compound, auriclosene (NVC-422), for global veterinary markets for companion animals. The Company received an option exercise fee and may receive future development and pre-commercial milestone payments as a result of the collaboration. The Company also expects to receive royalties on the sale of any commercial products in the companion animal field. Virbac’s option exercise follows its extensive testing of auriclosene for veterinary uses during the 12-month option period. The Company is recognizing the option exercise fee over its expected performance period of 10 years based on actual sales during this period. The Company did not recognize any revenue under the Virbac agreement during the three and nine months ended September 30, 2016 and 2015, respectively. The Company had a deferred revenue balance of $246 thousand as of both September 30, 2016 and December 31, 2015 related to this agreement, which consisted of the unamortized balances on the upfront technology access fee and option fee and support for ongoing research and development. NeutroPhase Distribution Agreements In January 2012, the Company entered into a distribution agreement with Pioneer Pharma Co., Ltd (“Pioneer”), a Shanghai-based company that markets high-end pharmaceutical products in China, for the commercialization of NeutroPhase in this territory. Under the terms of the agreement, the Company received an upfront payment of $313 thousand. NovaBay also received $313 thousand in January 2013, related to the submission of the first marketing approval for the product to the China Food and Drug Administration (“CFDA”) (formerly the SFDA, State Food and Drug Administration), which was submitted in December 2012. The distribution agreement provides that Pioneer is entitled to receive cumulative purchase discounts of up to $500 thousand upon purchase of the NeutroPhase product. The deferred revenue will be recognized as the purchase discounts are earned, with the remaining deferred revenue recognized ratably over the product distribution period. In September 2012, the Company entered into two agreements with Pioneer: (1) an international distribution agreement (the “Distribution Agreement”) and (2) a unit purchase agreement (the “Pioneer Purchase Agreement”). These agreements were combined and accounted for as one arrangement with one unit of accounting for revenue recognition purposes. Pursuant to the terms of the Distribution Agreement, Pioneer has the right to distribute NeutroPhase, upon receiving marketing approval from a regulatory authority, in certain territories in Asia (other than China). Upon execution of the Distribution Agreement, the Company received an upfront payment, which was recorded as deferred revenue. Pioneer is also obligated to make certain additional payments to the Company upon receipt of marketing approval. The Distribution Agreement further provides that Pioneer is entitled to a cumulative purchase discount not to exceed $500 thousand upon the purchase of the NeutroPhase product, payable in the Company’s unregistered restricted common stock. Pursuant to the Pioneer Purchase Agreement, the Company also received $2.5 million from Pioneer for the purchase of restricted units (comprising one share of common stock and a warrant for the purchase of one share of common stock). The unit purchase was completed in two tranches: (1) 32,000 units in September 2012; and (2) 48,000 units in October 2012, with both tranches at a purchase price of $31.25 per share. The fair value of the total units sold was $3.5 million, based upon the trading price of our common stock on the dates the units were purchased and the fair value of the warrants based on the Black-Scholes-Merton option pricing model. Because the aggregate fair value of the units on the dates of purchase exceeded the $2.5 million in proceeds received from the unit purchase by approximately $1.0 million, the Company reallocated $600 thousand from deferred revenue to stockholders’ equity as consideration for the purchase of the units. In December 2013, the Company announced it had expanded its NeutroPhase commercial partnership agreement with Pioneer. The expanded agreement includes licensing rights to two new products, Avenova and CelleRx, both developed internally by NovaBay. The expanded partnership agreement covers the commercialization and distribution of these products in China and 11 countries in Southeast Asia. Revenue has been recognized under this agreements as follows: Three Months Ended Nine Months Ended September 30, September 30, (in thousands) 2016 2015 2016 2015 Amortization of upfront technology access fee $ 6 $ 6 $ 64 $ 19 Product revenue - - 236 79 Total revenue recognized $ 6 $ 6 $ 300 $ 98 The Company had a deferred revenue balance of $1,319 thousand and $1,382 Avenova Distribution Agreements In November 2014, the Company signed a nationwide distribution agreement for its Avenova product with McKesson Corporation (“McKesson”) as part of the Company’s commercialization strategy. McKesson makes Avenova widely available in local pharmacies and major retail chains across the U.S., such as Wal-Mart, Costco, CVS and Target. In January 2015, the Company signed a nationwide distribution agreement with Cardinal Health. In April 2015, the Company also signed a nationwide distribution agreement with AmerisourceBergen to market Avenova. Since December 2015, the Company has signed nationwide distribution agreements with Willow Pharmacy, Allure Pharmacy, Smith Drug Company and Dakota Drug to market Avenova. During the three months ended September 30, 2016 and September 30, 2015, the Company earned $2,085 thousand and $321 thousand, During the nine months ended September 30, 2016 and September 30, 2015, the Company earned $4,302 thousand and $482 thousand respectively, in sales revenue for its Avenova product from its distribution agreements. The Company had a deferred revenue balance of $1,207 thousand and $24 thousand as of September 30, 2016 and December 31, 2015, respectively, for its Avenova product from its distribution agreements.

Note 14 - Employee Benefit Plan

Note 14 - Employee Benefit Plan	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 14. EMPLOYEE BENEFIT PLAN The Company has a 401(k) plan covering all eligible employees. The Company is not required to contribute to the plan and made no contributions during the nine months ended September 30, 2016.

Note 15 - Related Party Transac

Note 15 - Related Party Transactions	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 15. RELATED PARTY TRANSACTIONS Related Party Loans See Note 8, “Related Party Notes Payable” for a description of the Loan with the following related parties: Mr. Sieczkarek, Chairman of the Board, President and Chief Executive Officer of the Company; the Gail J. Maderis Revocable Trust, on behalf of Ms. Maderis, a Director of the Company; Dr. McPherson, a Director of the Company; and Pioneer Singapore and Mr. Fu, the Company’s two largest stockholders. The Loan was fully paid off on August 1, 2016. Related Party Financing See Note 11, “Stockholders’ Equity (Deficit)” – “Common Stock” for a description of the February 2016 Purchase Agreements and April 2016 Securities Purchase Agreement. The following related parties participated in both transactions: Mr. Sieczkarek, Chairman of the Board, President and Chief Executive Officer of the Company; and Pioneer Singapore and Mr. Fu, the Company’s two largest stockholders. Related Party Revenue The Company recognized related party revenues from product sales and license and collaboration fees of $6 thousand and $6 thousand for the three months ended September 30, 2016 and September 30, 2015, respectively, and $300 thousand and $98 thousand for the nine months ended September 30, 2016 and September 30, 2015, respectively. There were no related party accounts receivable as of September 30, 2016 and December 31, 2015. See Note 13, “License, Collaboration and Distribution Agreements - NeutroPhase Distribution Agreements,” Related Party Expenses The Company recognized related party commission fees of $548 thousand and $0 thousand for the three months ended September 30, 2016 and September 30, 2015, respectively, and $1,111 thousand and $408 thousand for the nine months ended September 30, 2016 and September 30, 2015, respectively. These fees were paid to China Kington, representing the commission on sale of the Company’s common stock and the exercise of the Company’s warrants. See Note 11, “Stockholders’ Equity (Deficit)” – “Common Stock” for additional information regarding such commissions.

Note 16 - Subsequent Events

Note 16 - Subsequent Events	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 16. SUBSEQUENT EVENTS On October 28, 2016, the Company received a letter from the NYSE MKT informing it that the Company is back in compliance with the NYSE MKT continued listing standards set forth in Part 10 of the NYSE MKT Company Guide (the “Company Guide”). Specifically, the Company has resolved the continued listing deficiencies with respect to Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide referenced in the NYSE MKT’s letters dated April 28, 2015, July 10, 2015 and March 17, 2016. The Company will be subject to ongoing review for compliance with NYSE MKT requirements as part of the NYSE MKT’s routine monitoring.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions for Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and notes required for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 4, 2016. The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries, as applicable.
Reclassification, Policy [Policy Text Block]	Reclassifications Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not change total assets, total liabilities, or total stockholders’ equity (deficit).
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, DermaBay, Inc., as applicable. DermaBay, Inc. was dissolved by the Company in April 2016. All inter-company accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.
Unaudited Interim Financial Information, Policy [Policy Text Block]	Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents and Short-Term Investments The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of September 30, 2016, and December 31, 2015, the Company’s cash and cash equivalents were held in three highly-rated, major financial institutions in the United States. The Company classifies all highly-liquid investments with a stated maturity of greater than three months at the date of purchase as short-term investments. Short-term investments generally consist of municipal and corporate debt securities. The Company has classified its short-term investments as available-for-sale. The Company does not intend to hold securities with stated maturities greater than twelve months until maturity. These securities are carried at fair value, with the unrealized gains and losses reported as a component of other comprehensive (loss) until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value below cost of any available-for-sale security that is determined to be other-than-temporary results in a revaluation of its carrying amount to fair value and an impairment charge to earnings, resulting in a new cost basis for the security. No such impairment charges were recorded for the periods presented. The interest income and realized gains and losses are included in other expense, net, within the consolidated statements of operations and comprehensive loss. Interest income is recognized when earned. As of September 30, 2016 and December 31, 2015, the Company had no short-term investments.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with three highly-rated, major financial institutions in the United States. Deposits in these banks may exceed the amount of federal insurance provided on such deposits. The Company does not believe it is exposed to significant credit risk due to the financial position of the financial institutions in which these deposits are held. During the three months and nine months ended September 30, 2016, revenues were derived primarily from sales of Avenova directly to doctors through the Company’s webstore and to three major distribution partners. During the three months and nine months ended September 30, 2015, revenues were derived primarily from one collaboration partner, service revenues and sales of NeutroPhase. As of September 30, 2016, 36%, 25% and 17% of accounts receivable were from three major distribution partners. As of December 31, 2015, 41% and 18% of accounts receivable were from two major distribution partners.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Our warrant liability is carried at fair value. The Company measures the fair value of financial assets and liabilities based on GAAP guidance, which defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. Under GAAP, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is also established, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities; Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identified amounts due that are in dispute and it believes are unlikely to be collected as of the end of September 30, 2016. As of September 30, 2016 and December 31, 2015, management had reserved $14 thousand and $40 thousand, respectively, primarily based on specific amounts that are in dispute and are over 120 days past due.
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes, and pumps; (2) goods in progress, which are normally unlabeled bottles; and (3) finished goods. Inventory is stated at the lower of cost or market value determined by the first-in, first-out method. The inventory allowance for lower cost or market, obsolete inventory, and excess inventory was $77 thousand and $45 thousand at September 30, 2016 and December 31, 2015, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five to seven years for office and laboratory equipment, three years for software and seven years for furniture and fixtures. Leasehold improvements are depreciated over the shorter of seven years or the lease term. The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred. In September 2016, the Company sub-leased its prior headquarters and determined that its leasehold improvements were impaired. This resulted in a $66 thousand impairment charge recorded to general and administrative expense for the third quarter of 2016, and is reflected in the results for the three and nine months ended September 30, 2016.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with GAAP, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use are present. Management periodically evaluates the carrying value of long-lived assets. During the first quarter of fiscal year 2016, the Company impaired a note receivable which was deemed to no longer be collectable, as the originator of the loan is not in business and the collateral held against the loan did not possess value in an amount sufficient to satisfy the loan. As a result, a $91 thousand impairment charge was recorded to research and development expense for the first quarter of fiscal year 2016, and is reflected in the results of the nine months ended September 30, 2016. There were no impairments during the three and nine months ended September 30, 2015. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the statements of operations.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) Accounting Standards Codification (“ASC”) 220, Comprehensive Income
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company sells products through a limited number of distributors and via its webstore. The Company generally records product sales upon shipment to the final customer for its webstore sales and upon shipment from its distributor to the final customers for its major distribution partners. The Company recognizes product revenue when: (i) persuasive evidence that a sale arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured. Revenue from sales transactions where the customer has the right to return the product is recognized at the time of sale only if: (i) the Company’s price to the customer is substantially fixed or determinable at the date of sale, (ii) the customer has paid the Company, or the customer is obligated to pay the Company and the obligation is not contingent on resale of the product, (iii) the customer's obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (iv) the customer acquiring the product for resale has economic substance apart from that provided by the Company, (v) the Company does not have significant obligations for future performance to directly bring about resale of the product by the customer, and (vi) the amount of future returns can be reasonably estimated. If these factors were to vary, the resulting change could have a material effect on our revenue recognition and on the Company’s results of operations. Product Revenue Allowances Product revenue is recognized, net of cash consideration paid to our customers and wholesalers, for services rendered by wholesalers in accordance with such wholesalers’ agreements and includes both a fixed rate per prescription shipped and monthly program management and data fees. These services are not deemed sufficiently separable from the customers' purchase of the product; therefore, they are recorded as a reduction of revenue at the time of revenue recognition. Other product revenue allowances include certain prompt pay discounts and allowances offered to our customers, program rebates and chargebacks. These product revenue allowances are recognized as a reduction of revenue or as a selling expense at the later of the date at which the related revenue is recognized or the date at which the allowance is offered. Other Revenue License and collaboration revenue is primarily generated through agreements with strategic partners for the development and commercialization of the Company’s product candidates. The terms of the agreements typically include non-refundable upfront fees, funding of research and development activities, and payments based upon achievement of certain milestones and royalties on net product sales. In accordance with authoritative guidance, the Company analyzes its multiple element arrangements to determine whether the elements can be separated. The Company performs its analysis at the inception of the arrangement and as each product or service is delivered. If a product or service is not separable, the combined deliverables are accounted for as a single unit of accounting, and revenue is recognized over the performance obligation period. The Company recognizes other revenue when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and risk of loss has passed; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured. If these factors were to vary, the resulting change could have a material effect on the Company’s revenue recognition and results of operations.
Cost of Sales, Policy [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third party manufacturing costs, shipping costs, and other cost of goods sold. Cost of goods sold also includes any necessary allowances for excess inventory that may expire and become unsalable. The amount charged for lower cost or market, obsolete inventory, and excess inventory expensed was $47 thousand and $84 thousand for the three and nine month periods ended September 30, 2016, respectively. The amount charged for lower cost or market, obsolete inventory, and excess inventory expensed was zero for the three and nine month periods ended September 30, 2015.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may vary depending on the type of item or service incurred, location of performance or production, level of availability of the item or service, and specificity required in production for certain compounds. The Company uses external service providers to conduct clinical trials, to manufacture supplies of product candidates and to provide various other research and development-related products and services. The Company’s research, clinical and development activities are often performed under agreements it enters into with external service providers. The Company estimates and accrues the costs incurred under these agreements based on factors such as milestones achieved, patient enrollment, estimates of work performed, and historical data for similar arrangements. As actual costs are incurred, the Company adjusts its accruals. Historically, the Company’s accruals have been consistent with management’s estimates, and no material adjustments to research and development expenses have been recognized. Subsequent changes in estimates may result in a material change in the Company’s expenses, which could also materially affect its results of operations.
Legal Costs, Policy [Policy Text Block]	Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Updates (“ASU”) No. 2014-12, Compensation-Stock Compensation (Topic 718)
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.
Warrant Liabilities [Policy Text Block]	Common Stock Warrant Liability For warrants that are issued or modified and there is a deemed possibility that the Company may have to settle the warrants in cash, or for warrants the Company issues or modifies that contain an exercise price adjustment feature that reduces the exercise price of the Company’s common stock eligible for purchase thereunder in the event that the Company subsequently issues equity instruments at a price lower than the exercise price of the warrants, the Company records the fair value of the issued or modified warrants as a liability at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss on the consolidated statements of operations and comprehensive loss. The fair values of these warrants have been determined using the Binomial Lattice (“Lattice”) valuation model, which provides for assumptions regarding volatility, call and put features and risk-free interest rates within the total period to maturity. These values are subject to a significant degree of the Company’s judgment.
Earnings Per Share, Policy [Policy Text Block]	Net (Loss) per Share The Company computes net (loss) per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods since their effect would be anti-dilutive. During the three months ended September 30, 2016 and 2015, and the nine months ended September 30, 2016 and 2015, there was no difference between basic and diluted EPS due to the Company’s net losses. The following table sets forth the calculation of basic EPS and diluted EPS: Three Months Ended Nine Months Ended September 30, September 30, (in thousands, except per share data) 2016 2015 2016 2015 Net loss $ (3,736 ) $ (5,242 ) $ (11,503 ) $ (14,769 ) Basic Shares 10,912,616 2,957,477 7,480,985 2,598,052 Add: shares issued upon assumed exercise of stock options and warrants — — — — Diluted shares 10,912,616 2,957,477 7,480,985 2,598,052 Basic and diluted net loss per share $ (0.34 ) $ (1.77 ) $ (1.54 ) $ (5.68 ) The following outstanding stock options and stock warrants were excluded from the diluted net loss per share computation, as their effect would have been anti-dilutive: Nine Months Ended September 30, (in thousands) 2016 2015 Period end stock options to purchase common stock 1,502 344 Period end common stock warrants 929 1,015 2,431 1,359
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) In March, April and May 2016, the FASB issued additional amendments to the new revenue guidance relating to reporting revenue on a gross versus net basis, identifying performance obligations, licensing arrangements, collectability, noncash consideration, presentation of sales tax, and transition. This new standard will replace all current GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition update guidance provides a unified model to determine how revenue is recognized. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The FASB has issued several updates to the standard which i) clarify the application of the principal versus agent guidance (ASU 2016-08); ii) clarify the guidance on inconsequential and perfunctory promises and licensing (ASU 2016-10) and iii) narrow-scope improvements and practical expedients (ASU 2016-12). On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. The Company is currently assessing the potential impact of this new standard on its consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory In August 2014, FASB issued ASU 2014-15, Presentation of Financial Statements Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Leases (Topic 840) In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230), effects of the adoption of ASU 2016-15 to its consolidated financial statements.

Note 2 - Summary of Significa23

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (in thousands, except per share data) 2016 2015 2016 2015 Net loss $ (3,736 ) $ (5,242 ) $ (11,503 ) $ (14,769 ) Basic Shares 10,912,616 2,957,477 7,480,985 2,598,052 Add: shares issued upon assumed exercise of stock options and warrants — — — — Diluted shares 10,912,616 2,957,477 7,480,985 2,598,052 Basic and diluted net loss per share $ (0.34 ) $ (1.77 ) $ (1.54 ) $ (5.68 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Nine Months Ended September 30, (in thousands) 2016 2015 Period end stock options to purchase common stock 1,502 344 Period end common stock warrants 929 1,015 2,431 1,359

Note 3 - Fair Value Measureme24

Note 3 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using (in thousands) Balance at September 30, 2016 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 100 $ 100 $ — $ — Total assets $ 100 $ 100 $ — $ — Liabilities Warrant liability $ 2,336 $ — $ — $ 2,336 Total liabilities $ 2,336 $ — $ — $ 2,336
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(in thousands) Warrant liability Fair value of warrant liability at December 31, 2015 $ 1,450 Increase in fair value at March 31, 2016 385 Fair value of warrant liability at March 31, 2016 1,835 Increase in fair value at June 30, 2016 424 Fair value of warrant liability at June 30, 2016 2,259 Increase in fair value on exercise date and at September 30, 2016 1,671 Fair market value of warrants transferred to equity upon exercise (1,594 ) Fair value of warrant liability at September 30, 2016 $ 2,336

Note 4 - Prepaid Expenses and25

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	(in thousands) September 30, 2016 December 31, 2015 Prepaid outsourced sales team $ 646 $ — Prepaid sales rebate 530 — Prepaid rent 196 — Prepaid research and development services 140 — Inventory deposit 29 84 Other 286 177 Total prepaid expenses and other current assets $ 1,827 $ 261

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(in thousands) September 30, 2016 December 31, 2015 Raw materials and supplies $ 769 $ 660 Goods in process — 248 Finished goods 392 482 Less allowance for obsolete inventory and lower cost of market (77 ) (45 ) Total inventory $ 1,084 $ 1,345

Note 6 - Property and Equipme27

Note 6 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	(in thousands) September 30, 2016 December 31, 2015 Office and laboratory equipment $ 214 $ 1,633 Furniture and fixtures 183 254 Software 100 37 Leasehold improvements 181 173 Total property and equipment, at cost 678 2,097 Less: accumulated depreciation (396 ) (1,702 ) Net property and equipment $ 282 $ 395

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	(in thousands) September 30, 2016 December 31, 2015 Research and development $ 12 $ 394 Employee payroll and benefits 449 614 Severance pay 512 590 Inventory 130 12 Sales rebate 149 150 Outsourced sales team 299 - Other 329 220 Total accrued liabilities $ 1,880 $ 1,980

Note 10 - Warrant Liability (Ta

Note 10 - Warrant Liability (Tables)	9 Months Ended
	Sep. 30, 2016
July 2011, Long-term, Short-term, and October 2015 Warrants [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Dollars in thousands Shares Warrant Liability July 2011 Warrants 100,507 $ 316 Long-Term Warrants 127,919 413 Short-Term Warrants 172,667 556 October 2015 Warrants 318,602 1,051 719,695 $ 2,336
Schedule of Derivative Instruments [Table Text Block]	Assumption Expected price volatility 80.00 % Expected term (in years) 4.36 Risk-free interest rate 1.23 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.60 Period Ended Assumption September 30, 2016 December 31, 2015 Expected price volatility 100.00 % 80.00 % Expected term (in years) 3.43 4.18 Risk-free interest rate 0.94 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.14 $ 1.10 Assumption Expected price volatility 80.00 % Expected term (in years) 4.36 Risk-free interest rate 1.23 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.78 Period Ended Assumption September 30, 2016 December 31, 2015 Expected price volatility 100.00 % 80.00 % Expected term (in years) 3.43 4.18 Risk-free interest rate 0.94 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.23 $ 1.16 Period Ended Assumption September 30, 2016 December 31 , 2015 Expected price volatility 100.00 % 80.00 % Expected term (in years) 3.43 4.18 Risk-free interest rate 0.94 % 1.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.22 $ 1.16 Assumption Expected price volatility 75.50 % Expected term (in years) 5.00 Risk-free interest rate 1.38 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.82 Period Ended Assumption September 30, 2016 December 31, 2015 Expected price volatility 95.00 % 77.50 % Expected term (in years) 4.08 4.83 Risk-free interest rate 1.02 % 1.72 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.30 $ 1.21
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	(in thousands, except for exercise price) Warrants Weighted- Average Exercise Price Warrants outstanding December 31, 2015 1,458 $ 5.19 Warrants granted 3,087 1.91 Warrants exercised (3,613 ) 1.91 Warrants expired (3 ) 78.13 Warrants outstanding September 30, 2016 929 $ 2.12

Note 11 - Stockholders' Equit30

Note 11 - Stockholders' Equity (Deficit) (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	(in thousands, except for exercise price) Warrants Weighted- Average Exercise Price Warrants outstanding December 31, 2015 1,458 $ 5.19 Warrants granted 3,087 1.91 Warrants exercised (3,613 ) 1.91 Warrants expired (3 ) 78.13 Warrants outstanding September 30, 2016 929 $ 2.12

Note 12 - Equity-based Compen31

Note 12 - Equity-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Nonemployee [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, Assumption 2016 2015 Expected price volatility 88 % 79 % Expected term (in years) 9.99 9.38 Risk-free interest rate 1.61 % 2.07 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.29 $ 13.50
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	(in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2015 388 $ 32.03 6.2 19 Options granted 1,199 $ 2.71 Restricted stock units granted 74 $ — Options exercised - $ — Restricted stock units vested (74 ) $ — Options forfeited/cancelled/expired (85 ) $ 36.87 Outstanding at September 30, 2016 1,502 $ 8.64 8.9 $ 1,718 Vested and expected to vest at September 30, 2016 1,478 $ 8.40 8.9 $ 1,691 Vested at September 30, 2016 325 $ 27.04 6.2 $ — Exercisable at September 30, 2016 325 $ 27.04 6.2 $ —
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine months ended September 30, Assumption 2016 2015 Expected price volatility 84 % 74 % Expected term (in years) 7.03 5.35 Risk-free interest rate 1.56 % 1.65 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.03 $ 10.00
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (in thousands) 2016 2015 2016 2015 Research and development $ 63 $ 86 $ 142 $ 266 Sales and marketing 62 - 113 - General and administrative 585 135 972 743 Total stock-based compensation expense $ 710 $ 221 $ 1,227 $ 1,009

Note 13 - License, Collaborat32

Note 13 - License, Collaboration and Distribution Agreements (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (in thousands) 2016 2015 2016 2015 Amortization of upfront technology access fee $ 6 $ 6 $ 64 $ 19 Product revenue - - 236 79 Total revenue recognized $ 6 $ 6 $ 300 $ 98

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) $ in Thousands	Dec. 18, 2015	Aug. 31, 2007	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	25
Minimum [Member] | Scenario, Forecast [Member]
Net Cash Provided by (Used in) Operating Activities, Continuing Operations					$ 19,400
Number of Operating Segments			1			4
Number of Subsidiaries		2
Cash and Cash Equivalents, at Carrying Value			$ 9,430	$ 3,383		$ 2,385	$ 5,429
Net Cash Provided by (Used in) Operating Activities, Continuing Operations			$ (11,441)	$ (14,070)

Note 2 - Summary of Significa34

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Jun. 30, 2015
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Largest Distribution Partner [Member]
Concentration Risk, Percentage			36.00%		41.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Second-largest Distribution Partner [Member]
Concentration Risk, Percentage			25.00%		18.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Third-largest Distribution Partner [Member]
Concentration Risk, Percentage			17.00%
Allowance for Doubtful Accounts [Member]
Valuation Allowances and Reserves, Balance	$ 14,000		$ 14,000		$ 40,000
Allowance for Obsolete Inventory [Member]
Inventory Valuation Reserves	47,000	$ 0	47,000	$ 0
Allowance for Excess Inventory [Member]
Inventory Valuation Reserves	84,000		$ 84,000			$ 0
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life			5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life			7 years
Software Development [Member]
Property, Plant and Equipment, Useful Life			3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life			7 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life			7 years
General and Administrative Expense [Member]
Impairment of Leasehold	66,000
Research and Development Expense [Member]
Impairment of Long-Lived Assets Held-for-use			$ 91,000
Short-term Investments	0		0		0
Inventory Valuation Reserves	$ 77,000		77,000		$ 45,000
Impairment of Leasehold			$ 66,000
Impairment of Long-Lived Assets Held-for-use		$ 0		$ 0

Note 2 - Summary of Significa35

Note 2 - Summary of Significant Accounting Policies - Reconciliation Between Basic Net Income (Loss) Per Share and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net loss	$ (3,736)	$ (5,242)	$ (11,503)	$ (14,769)
Basic Shares (in shares)	10,912,616	2,957,477	7,480,985	2,598,052
Diluted shares (in shares)	10,912,616	2,957,477	7,480,985	2,598,052
Basic and diluted net loss per share (in dollars per share)	$ (0.34)	$ (1.77)	$ (1.54)	$ (5.68)

Note 2 - Summary of Significa36

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Employee Stock Option [Member]
Period end stock options to purchase common stock (in shares)	1,502	344
Warrant [Member]
Period end stock options to purchase common stock (in shares)	929	1,015
Period end stock options to purchase common stock (in shares)	2,431	1,359

Note 3 - Fair Value Measureme37

Note 3 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Other Nonoperating Gains (Losses)	$ (1,671)	$ 139	$ (2,480)	$ 173

Note 3 - Fair Value Measureme38

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Cash equivalents	$ 100
Total assets	100
Liabilities
Warrant liability
Total liabilities
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets
Cash equivalents
Total assets
Liabilities
Warrant liability
Total liabilities
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets
Cash equivalents
Total assets
Liabilities
Warrant liability	2,336
Total liabilities	2,336
Fair Value, Measurements, Recurring [Member]
Assets
Cash equivalents	100
Total assets	100
Liabilities
Warrant liability	2,336
Total liabilities	2,336
Total assets	$ 286	$ 177

Note 3 - Fair Value Measureme39

Note 3 - Fair Value Measurements - Fair Value of Warrant Liability (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2016	Sep. 30, 2015
Fair value of warrant liability	$ 2,259	$ 1,835	$ 1,450	$ 1,450
Fair Value Adjustment of Warrants	1,671	424	385	270
Fair value of warrant liability	2,336	$ 2,259	$ 1,835	$ 2,336
Fair market value of warrants transferred to equity upon exercise	$ (1,594)

Note 4 - Prepaid Expenses and40

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Prepaid outsourced sales team	$ 646
Prepaid sales rebate	530
Prepaid rent	196
Prepaid research and development services	140
Inventory deposit	29	84
Other	286	177
Total prepaid expenses and other current assets	$ 1,827	$ 261

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Raw materials and supplies	$ 769	$ 660
Goods in process		248
Finished goods	392	482
Less allowance for obsolete inventory and lower cost of market	(77)	(45)
Total inventory	$ 1,084	$ 1,345

Note 6 - Property and Equipme42

Note 6 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
General and Administrative Expense [Member] | Sublease Agreement [Member]
Impairment of Leasehold	$ 66,000		$ 66,000
General and Administrative Expense [Member]
Impairment of Leasehold	66,000
Research and Development Expense [Member] | Laboratory Equipment [Member]
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	232,000		232,000
Impairment of Leasehold			66,000
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property			232,000	1,000
Depreciation, Depletion and Amortization	$ 31,000	$ 41,000	$ 98,000	$ 123,000

Note 6 - Property and Equipme43

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Equipment [Member]
Property and equipment, at cost	$ 214	$ 1,633
Furniture and Fixtures [Member]
Property and equipment, at cost	183	254
Software and Software Development Costs [Member]
Property and equipment, at cost	100	37
Leasehold Improvements [Member]
Property and equipment, at cost	181	173
Property and equipment, at cost	678	2,097
Less: accumulated depreciation	(396)	(1,702)
Net property and equipment	$ 282	$ 395

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Research and development	$ 12	$ 394
Employee payroll and benefits	449	614
Severance pay	512	590
Inventory	130	12
Sales rebate	149	150
Outsourced sales team	299
Other	329	220
Total accrued liabilities	$ 1,880	$ 1,980

Note 8 - Related Party Notes 45

Note 8 - Related Party Notes Payable (Details Textual) - USD ($)	Aug. 01, 2016	May 06, 2016	Jan. 12, 2016	Dec. 30, 2015
Notes [Member] | Lenders [Member]
Proceeds from Related Party Debt				$ 3,000,000
Related Party Transaction, Rate				6.00%
Notes [Member] | China Kingston [Member]
Loan Facilitation Consideration, Lead Financings Period, Maximum				2 years
Loan Facilitation Consideration Lead Financings, Three Consecutive Months Cash Flow, Minimum				$ 0
Loan Facilitation Consideration Financing Provided By Board and Management on Next Financing, Percentage				9.00%
Loan Facilitation Consideration, Number of New Appointments to Board				2
Promissory Note 1 [Member] | Board of Directors Chairman [Member]
Proceeds from Related Party Debt				$ 199,000
Promissory Note 2 [Member] | Director [Member]
Proceeds from Related Party Debt				71,000
Promissory Note 3 [Member] | Director [Member]
Proceeds from Related Party Debt				20,000
Promissory Note 4 [Member] | Pioneer Pharma Co. [Member]
Proceeds from Related Party Debt				$ 1,400,000
Promissory Note 5 [Member] | Mr. Fu [Member]
Proceeds from Related Party Debt			$ 1,400,000
Debt Instrument, Term			3 years
Private Placement [Member]
Repayments of Related Party Debt	$ 520,000	$ 2,500,000
Proceeds from Issuance of Private Placement	$ 11,800,000	$ 11,800,000

Note 9 - Commitments and Cont46

Note 9 - Commitments and Contingencies (Details Textual)	Aug. 24, 2016USD ($)ft²	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Jul. 11, 2016ft²
KBSIII Towers [Member] | First 12 Months of Operating Lease [Member]
Lessee Leasing Arrangements, Operating Leases, Monthly Base Rental Rate	4.15
Lessee Leasing Arrangement, Operating Leases, Annual Base Rental Rate Amount	$ 338,390
KBSIII Towers [Member] | Every 11 Months of Operating Lease [Member]
Lessee Leasing Arrangements, Operating Leases, Increase in Monthly Base Rental Rate, Percentage	3.00%
KBSIII Towers [Member] | First 61 to 63 Months of Operating Lease [Member] | Maximum [Member]
Lessee Leasing Arrangements, Operating Leases, Monthly Base Rental Rate	4.81
Lessee Leasing Arrangement, Operating Leases, Annual Base Rental Rate Amount	$ 450,250
KBSIII Towers [Member] | Last Day of 60th Month of Operating Lease [Member] | Maximum [Member]
Lessee Leasing Arrangements, Operating Leases, Standby Letter of Credit, Reduced Amount	151,823
KBSIII Towers [Member] | Other Assets [Member]
Lessee Leasing Arrangements, Operating Leases, Standby Letter of Credit, Initial Amount	$ 323,658
KBSIII Towers [Member]
Lessee Leasing Arrangements, Operating Leases, Square Feet of Property | ft²	7,799
Lessee Leasing Arrangements, Operating Leases, Term of Contract	5 years 90 days
Lessee Leasing Arrangements, Operating Leases, Renewal Term	5 years
Lessee Leasing Arrangements, Operating Leases, Earliest Period Prior to Expiration of Current Term to Renew Lease	1 year
Lessee Leasing Arrangements, Operating Leases, Latest Period Prior to Expiration of Current Term to Renew Lease	270 days
Lessee Leasing Arrangements, Operating Leases, Direct Expenses of Premises, Percentage	2.16%
Lessee Leasing Arrangements, Operating Leases, Abatement Term for Monthly Base Rental Payments	90 days
Sublease Agreement [Member] | General and Administrative Expense [Member]
Impairment of Leasehold		$ 66,000		$ 66,000
General and Administrative Expense [Member]
Noncash Loss on Sublease		26,000		26,000
Impairment of Leasehold		66,000
Area of Property in Sublease Agreement | ft²						16,465
Impairment of Leasehold				66,000
Operating Leases, Rent Expense		$ 360,000	$ 257,000	$ 873,000	$ 758,000

Note 10 - Warrant Liability (De

Note 10 - Warrant Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 01, 2016	May 05, 2016	Apr. 04, 2016	Feb. 16, 2016	Oct. 27, 2015	Oct. 22, 2015	Mar. 03, 2015	Jul. 31, 2011	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 29, 2016	Sep. 28, 2016	Jun. 30, 2016	May 31, 2016	Mar. 31, 2016	Feb. 29, 2016	Dec. 31, 2015	Jan. 05, 2012
Private Placement [Member] | Short-term Warrants [Member]
Warrant Expiration Term						1 year 90 days
Private Placement [Member] | Long-term Warrants [Member]
Warrant Expiration Term						5 years
Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.91
Length of Notice Required to Investors Prior to Issuance of New Securities						20 days	2 days
Warrant Expiration Term			4 years
Stock Issued During Period, Shares, New Issues	2,094,241	4,079,058	6,173,299
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,047,121	2,039,530	3,086,651
Underwriting Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5
Warrant Expiration Term					5 years
Stock Issued During Period, Shares, New Issues					492,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					442,802
Proceeds from Issuance of Stock and Warrants					$ 2,100
Warrants and Rights Outstanding					1,300
Mr. Fu [Member] | July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																		$ 1.81
Mr. Fu [Member]
Stock Issued During Period, Shares, New Issues				696,590
Short-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 15
Warrants and Rights Outstanding									$ 556		$ 556
Long-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 16.25
Warrants and Rights Outstanding									$ 413		$ 413
The 2011 and March 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 5
Warrants to be Exercised at Lower Price Stock Price Trigger						5
Class of Warrant or Right Price Protection Provision Exchangeable Securities Exercise Price Trigger						$ 5
Warrants and Rights Outstanding					1,800
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									518,281		518,281
Class of Warrant or Right, Exercised During Period									518,281
Proceeds from Warrant Exercises									$ 938
Other Nonoperating Gains (Losses)											$ 1,600
The 2011 Warrants [Member]
Warrants and Rights Outstanding					$ 361				$ 316		$ 316
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued								139,520
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 33.25	$ 2.12		$ 2.12		$ 3.15	$ 19.50					$ 5.19
Minimum Common Stock Closing Bid Price Per Share																				$ 66.50
Stock Issued During Period, Shares, New Issues				1,518,567
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									3,613,261		3,613,261					2,039,530
Warrants and Rights Outstanding									$ 2,336		$ 2,336				$ 2,259		$ 1,835		$ 1,450
Proceeds from Warrant Exercises									6,600
Other Nonoperating Gains (Losses)									$ (1,671)	$ 139	$ (2,480)	$ 173

Note 10 - Warrant Liability - T

Note 10 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details) - Warrant Fair Value [Member] - $ / shares	Oct. 27, 2015	Sep. 30, 2016	Dec. 31, 2015
The 2011 Warrants [Member]
Expected price volatility	80.00%	100.00%	80.00%
Expected term (in years)	4 years 131 days	3 years 156 days	4 years 65 days
Risk-free interest rate	1.23%	0.94%	1.58%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.60	$ 3.14	$ 1.10
Expected price volatility	80.00%	100.00%	80.00%
Expected term (in years)	4 years 131 days	3 years 156 days	4 years 65 days
Risk-free interest rate	1.23%	0.94%	1.58%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.60	$ 3.14	$ 1.10
Short-term Warrants [Member]
Expected price volatility		100.00%	80.00%
Expected term (in years)		3 years 156 days	4 years 65 days
Risk-free interest rate		0.94%	1.58%
Dividend yield		0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)		$ 3.23	$ 1.16
Expected price volatility		100.00%	80.00%
Expected term (in years)		3 years 156 days	4 years 65 days
Risk-free interest rate		0.94%	1.58%
Dividend yield		0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)		$ 3.23	$ 1.16
Long-term Warrants [Member]
Expected price volatility		100.00%	80.00%
Expected term (in years)		3 years 156 days	4 years 65 days
Risk-free interest rate		0.94%	1.58%
Dividend yield		0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)		$ 3.22	$ 1.16
Expected price volatility		100.00%	80.00%
Expected term (in years)		3 years 156 days	4 years 65 days
Risk-free interest rate		0.94%	1.58%
Dividend yield		0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)		$ 3.22	$ 1.16
October 2015 Warrants [Member]
Expected price volatility	75.50%	95.00%	77.50%
Expected term (in years)	5 years	4 years 29 days	4 years 302 days
Risk-free interest rate	1.38%	1.02%	1.72%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.82	$ 3.30	$ 1.21
Expected price volatility	75.50%	95.00%	77.50%
Expected term (in years)	5 years	4 years 29 days	4 years 302 days
Risk-free interest rate	1.38%	1.02%	1.72%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.82	$ 3.30	$ 1.21
Short-term and Long-term Warrants [Member]
Expected price volatility	80.00%
Expected term (in years)	4 years 131 days
Risk-free interest rate	1.23%
Dividend yield	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.78
Expected price volatility	80.00%
Expected term (in years)	4 years 131 days
Risk-free interest rate	1.23%
Dividend yield	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 2.78

Note 10 - Warrant Liability - O

Note 10 - Warrant Liability - Outstanding Warrant Liability (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Oct. 27, 2015
The 2011 Warrants [Member]
July 2011 Warrants (in shares)	100,507
Warrants and Rights Outstanding	$ 316				$ 361
Long-term Warrants [Member]
July 2011 Warrants (in shares)	127,919
Warrants and Rights Outstanding	$ 413
Short-term Warrants [Member]
July 2011 Warrants (in shares)	172,667
Warrants and Rights Outstanding	$ 556
October 2015 Warrants [Member]
July 2011 Warrants (in shares)	318,602
Warrants and Rights Outstanding	$ 1,051
July 2011, Long-term, Short-term, and October 2015 Warrants [Member]
July 2011 Warrants (in shares)	719,695
Warrants and Rights Outstanding	$ 2,336
July 2011 Warrants (in shares)	929,000			1,458,000
Warrants and Rights Outstanding	$ 2,336	$ 2,259	$ 1,835	$ 1,450

Note 11 - Stockholders' Equit50

Note 11 - Stockholders' Equity (Deficit) (Details Textual) $ / shares in Units, $ in Thousands	Sep. 29, 2016$ / shares	Aug. 01, 2016USD ($)shares	May 05, 2016USD ($)shares	Apr. 04, 2016USD ($)$ / sharesshares	Feb. 16, 2016USD ($)$ / sharesshares	Dec. 18, 2015	Sep. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)	Sep. 28, 2016$ / shares	May 31, 2016shares	Feb. 29, 2016$ / shares	Dec. 31, 2015$ / sharesshares	Jul. 31, 2011$ / shares
Dr. Dean Rider [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues				52,356
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				26,178
Mr. Andy R. Geckler [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues				52,356
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				26,178
Pioneer Pharma Co. [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues				2,617,802
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,308,902
Mr. Jian Ping Fu [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues				1,937,173
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				968,587
Mr. Sieczkarek [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues				523,560
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				261,780
Mrs. Ping Huang [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues				523,560
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				261,780
Mr. Hai Dong Pang [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues				209,424
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				104,712
Mr. Ying Ping Wang [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues				104,712
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				52,356
Mr. Blake F. Andros [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues				100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				50,000
Children's Brain Disease Foundation [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues				52,356
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				26,178
Private Placement [Member] | Minimum [Member]
Common Stock, Closing Price | $ / shares				$ 4
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		2,094,241	4,079,058	6,173,299
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,047,121	2,039,530	3,086,651
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.01
Sale of Stock, Consideration Received on Transaction | $		$ 4,000	$ 7,800	$ 11,800
Warrant Expiration Term				4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.91
Number of Sequential Trading Days				5 days
Number of Tranches for Private Placement				2
Mr. Fu [Member] | July 2011, March 2015, and October 2015 Warrants [Member]
Shares Issued, Price Per Share | $ / shares														$ 1.81
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 1.81
Mr. Fu [Member]
Stock Issued During Period, Shares, New Issues					696,590
Shares Issued, Price Per Share | $ / shares					$ 1.81
Pioneer Pharma Co. [Member]
Stock Issued During Period, Shares, New Issues					696,590
Shares Issued, Price Per Share | $ / shares					$ 1.91
Mr. Sieczkarek [Member]
Stock Issued During Period, Shares, New Issues					125,387
Shares Issued, Price Per Share | $ / shares					$ 1.91
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio						25
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							518,281			518,281
Proceeds from Warrant Exercises | $							$ 938
General and Administrative Expense [Member]
Fair Value Adjustment of Warrants | $										$ 270
Preferred Stock, Shares Outstanding							0			0					0
Stock Issued During Period, Shares, New Issues					1,518,567
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							3,613,261			3,613,261			2,039,530
Preferred Stock, Shares Authorized							5,000,000			5,000,000
Stock Issued During Period, Value, New Issues | $					$ 2,800
Common Stock, Par or Stated Value Per Share | $ / shares							$ 0.01			$ 0.01					$ 0.01
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.15						$ 2.12			$ 2.12		$ 19.50			$ 5.19	$ 33.25
Private Placement, Commission Percentage				6.00%
Proceeds from Warrant Exercises | $							$ 6,600
Class of Warrants or Rights, Exercises in Period							3,613,261			3,613,000
Warrants Exercised, Commission Percentage							6.00%			6.00%
Warrants Exercised, Commission Paid | $							$ 338			$ 338
Class of Warrant or Right, Exercise Price, Discount from Market Price	16.00%
Fair Value Adjustment of Warrants | $							$ 1,671	$ 424	$ 385	$ 270

Note 11 - Stockholders' Equit51

Note 11 - Stockholders' Equity - Outstanding Warrants (Details) - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Warrants outstanding (in shares)		1,458,000
Weighted-average exercise price, warrants outstanding (in dollars per share)		$ 5.19
Warrants granted (in shares)		3,087,000
Weighted-average exercise price, warrants granted (in dollars per share)		$ 1.91
Warrants exercised (in shares)	(3,613,261)	(3,613,000)
Warrants exercised (in dollars per share)		$ 1.91
Warrants expired (in shares)		(3,000)
Weighted-average exercise price, warrants expired (in dollars per share)		$ 78.13
Warrants outstanding (in shares)	929,000	929,000
Weighted-average exercise price, warrants outstanding (in dollars per share)	$ 2.12	$ 2.12

Note 12 - Equity-based Compen52

Note 12 - Equity-based Compensation (Details Textual) - USD ($)	May 26, 2016	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
2007 Omnibus Incentive Plan [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent								110.00%
2007 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	1,124,826
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,124,836
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		97,200					97,200	97,200
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent								100.00%
Share-based Compensation Arrangement by Share-based Payment Award Threshold Purchase Price of Common Stock Percent								10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								4 years
Nonemployee [Member]
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued								89,000	12,000
Stock Issued During Period, Shares, Issued for Services								10,000	1,000
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								1,110,000	26,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period								64,000	6,000
Allocated Share-based Compensation Expense		$ 610,000		$ 192,000				$ 1,022,000	$ 869,000
Mr. Cashion and Mr. Wicks [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					4 years	90 days
Allocated Share-based Compensation Expense					$ 185,000
Mr. Radaelli and Mr. McPherson [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			90 days				4 years
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost							$ 58,000
Nonemployee [Member]
Allocated Share-based Compensation Expense		$ 100,000		$ 29,000				$ 205,000	140,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								1 year 306 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0		0				0
Proceeds from Stock Options Exercised		$ 0						$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value									4,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		1,900,000					$ 1,900,000	$ 1,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								1,199
Allocated Share-based Compensation Expense		$ 710,000		$ 221,000				$ 1,227,000	$ 1,009,000

Note 12 - Equity-based Compen53

Note 12 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Restricted Stock Units (RSUs) [Member]
Restricted stock units granted (in shares)	74
Restricted stock units vested (in shares)	(74)
Options outstanding (in shares)	388
Weighted-average exercise price (in dollars per share)	$ 32.03
Weighted-average remaining contractual life	8 years 328 days	6 years 73 days
Aggregate intrinsic value	$ 1,718	$ 19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,199
Weighted-average exercise price, options granted (in dollars per share)	$ 2.71
Options forfeited/cancelled/expired (in shares)	(85)
Weighted-average exercise price, options forfeited/cancelled/expired (in dollars per share)	$ 36.87
Options outstanding (in shares)	1,502	388
Weighted-average exercise price (in dollars per share)	$ 8.64	$ 32.03
Options, vested and expected to vest (in shares)	1,478
Weighted-average exercise price, vested and expected to vest (in dollars per share)	$ 8.40
Weighted-average remaining contractual life, vested and expected to vest	8 years 328 days
Aggregate intrinsic value, vested and expected to vest	$ 1,691
Options, vested (in shares)	325
Weighted-average exercise price, vested (in dollars per share)	$ 27.04
Weighted-average remaining contractual life	6 years 73 days
Options, exercisable (in shares)	325
Weighted-average exercise price, exercisable (in dollars per share)	$ 27.04
Weighted-average remaining contractual life, exercisable	6 years 73 days

Note 12 - Equity-based Compen54

Note 12 - Equity-based Compensation - The Weighted-average Assumptions Used in Determining the Value of Options Granted (Details) - Employee [Member] - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Expected price volatility	84.00%	74.00%
Expected term (in years)	7 years 10 days	5 years 127 days
Risk-free interest rate	1.56%	1.65%
Dividend yield	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 2.03	$ 10

Note 12 - Equity-based Compen55

Note 12 - Equity-based Compensation - The Weighted-average Assumptions Used in Determining the Value of Options Granted Non-employee (Details) - Nonemployee [Member] - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Expected price volatility	88.00%	79.00%
Expected term (in years)	9 years 361 days	9 years 138 days
Risk-free interest rate	1.61%	2.07%
Dividend yield	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 2.29	$ 13.50

Note 12 - Equity-based Compen56

Note 12 - Equity-based Compensation - Summary of the Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	$ 63	$ 86	$ 142	$ 266
Selling and Marketing Expense [Member]
Allocated Share-based Compensation Expense	62		113
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	585	135	972	743
Allocated Share-based Compensation Expense	$ 710	$ 221	$ 1,227	$ 1,009

Note 13 - License, Collaborat57

Note 13 - License, Collaboration and Distribution Agreements (Details Textual) $ / shares in Units, xbrli-pure in Millions	1 Months Ended				2 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2013USD ($)	Oct. 31, 2012USD ($)$ / sharesshares	Sep. 30, 2012USD ($)$ / sharesshares	Jan. 31, 2012USD ($)	Oct. 31, 2012USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2015USD ($)
Virbac [Member]
Deferred Revenue, Revenue Recognized						$ 0	$ 0	$ 0	$ 0
Deferred Revenue						246,000		246,000			$ 246,000
Neutrophase [Member]
Deferred Revenue						1,319,000		1,319,000			1,382,000
Avenova Distribution Agreements [Member]
Deferred Revenue						1,207,000		1,207,000			$ 24,000
Contracts Revenue						$ 2,085,000	$ 321,000	$ 4,302,000	$ 482,000
Restricted Stock [Member] | Pioneer Pharma Co. [Member]
Unit Purchase Agreement Shares Per Unit | $ / shares					$ 1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares		1			1
Tranche One [Member]
Purchase Agreement Unit Price Per Share | $ / shares			$ 31.25
Purchase Agreement Units | shares			32,000
Tranche Two [Member]
Purchase Agreement Unit Price Per Share | $ / shares		$ 31.25
Purchase Agreement Units | shares		48,000
Purchase Unit Agreement Total Units Fair Value		$ 3,500,000
Reallocated from Deferred Revenue [Member]
Stockholders' Equity, Period Increase (Decrease)					$ 600,000
Milestone Payments [Member]
Contracts Revenue										$ 500,000
Maximum [Member]
Sales Discounts, Goods			$ 500,000
Restricted Stock Purchase [Member]
Contracts Revenue					$ 2,500,000
Fees and Commissions, Other				$ 313,000
Contracts Revenue	$ 313,000
Excess Fair Value Over Proceeds Received From Purchase		1			1

Note 13 - License, Collaborat58

Note 13 - License, Collaboration and Distribution Agreements - Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Pioneer Pharma Co. [Member] | Neutrophase [Member]
Product revenue			$ 236	$ 79
Total revenue recognized	6	6	300	98
Pioneer Pharma Co. [Member]
Amortization of upfront technology access fee	6	6	64	19
Product revenue	3,262	1,136	7,571	2,559
Total revenue recognized	$ 3,438	$ 1,200	$ 7,820	$ 2,746

Note 14 - Employee Benefit Pl59

Note 14 - Employee Benefit Plan (Details Textual)	9 Months Ended
	Sep. 30, 2016USD ($)
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0

Note 15 - Related Party Trans60

Note 15 - Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Amortization Revenue [Member] | Neutrophase [Member]
Other Income	$ 6,000	$ 6,000	$ 300,000	$ 98,000
China Kingston [Member] | Related-party Commission Fees [Member]
Related Party Transaction, Expenses from Transactions with Related Party	548,000	$ 0	1,111,000	$ 408,000
Accounts Receivable, Related Parties	$ 0		$ 0		$ 0